Solid Tumours Clinical Trial
Official title:
A Randomised, Open-label, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of AZD1775 After Oral Dosing of a Capsule Formulation in Patients With Advanced Solid Tumours
The purpose of this study is to assess the effect of food on the pharmacokinetics (PK) of a single dose of AZD1775 (printed capsules) in patients with advanced solid tumours.
This is a Phase I, open-label, randomised, 2-period crossover design study in patients with
advanced solid tumours.
The purpose of this study is to assess the effect of food on the pharmacokinetics (PK) of a
single dose of AZD1775 (printed capsules).In addition single dose safety and tolerability
data will be gathered.
Patients will be screened within 28 days of Day 1 of the first treatment period (Period 1).
Patients will take part in 2 randomised treatment sequences each separated by a washout
period of at least 5 and no more than 14 days.
During Period 1, prior to administration of the first dose of study treatment, each patient
will be randomised to 1 of 2 treatment sequences (Fasted-Fed or Fed-Fasted) to receive a
single oral dose of 300 mg AZD1775 in each of the 2 treatment periods as follows:
- Fasted (Treatment A): Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules).
- Fed (Treatment B): Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules).
Pharmacokinetic and safety assessments will be obtained for up to 72 hours post-dose in each
treatment period.
On completion of the study (ie, after collection of 72-hour PK sample and safety in period 2)
patients will be evaluated per current assessments for their eligibility and interest to
enrol into the open-label continued treatment access study (D6014C000007).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01921140 -
To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours
|
Phase 1 | |
| Completed |
NCT00732420 -
Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03572192 -
Tissue Collection Framework To Improve Outcomes In Solid Tumours
|
||
| Completed |
NCT02360345 -
Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly
|
Phase 1 | |
| Completed |
NCT02264418 -
Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours
|
Phase 1 | |
| Completed |
NCT02093351 -
To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer
|
Phase 1 | |
| Completed |
NCT01956669 -
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT02215850 -
Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours
|
Phase 1 | |
| Recruiting |
NCT02263950 -
A Phase 1/2a Study of LON002 in Subjects With Advanced Solid Tumours
|
Phase 1/Phase 2 | |
| Completed |
NCT01931761 -
Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers
|
Phase 1 | |
| Completed |
NCT01900028 -
To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours
|
Phase 1 | |
| Completed |
NCT00136578 -
Ispinesib In Combination With Carboplatin In Patients With Solid Tumors
|
Phase 1 | |
| Completed |
NCT01184274 -
A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia
|
Phase 1 | |
| Withdrawn |
NCT03266159 -
A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT01894256 -
Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function
|
Phase 1 | |
| Completed |
NCT01974349 -
To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
|
Phase 1 | |
| Completed |
NCT02923947 -
Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment
|
Phase 1 | |
| Completed |
NCT02063204 -
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects
|
Phase 1 | |
| Completed |
NCT02056392 -
To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
|
Phase 1 | |
| Completed |
NCT00742131 -
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors
|
Phase 1 |